Trial Profile
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms AGIR
- 30 Jun 2023 Planned End Date changed from 1 Apr 2023 to 23 Mar 2024.
- 30 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2020 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.